Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications

American Journal of Psychiatry

Volumn 160, Issue 2, 2003, Pages 310-315

  Sernyak, Michael J ^a   Leslie, Douglas ^b   Rosenheck, Robert ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; FOLLOW UP; HEALTH CARE SYSTEM; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS OF COVARIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; AMBULATORY CARE; COMPARATIVE STUDY; DATA BASE; DRUG UTILIZATION; FEMALE; GOVERNMENT; HEALTH SERVICES RESEARCH; MALE; META ANALYSIS; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; PSYCHOLOGICAL RATING SCALE; STATISTICS; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DATABASE MANAGEMENT SYSTEMS; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES RESEARCH; HUMANS; MALE; META-ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 0037317705     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.2.310     Document Type: Article

References (23)

1. Rosenheck R, Stolar M, Fontana A: Outcomes monitoring and the testing of new psychiatric treatments: work therapy in the treatment of chronic post-traumatic stress disorder. Health Serv Res 2001; 35:133-149
2. Steinwachs DM, Wu AW, Skinner EA: How will outcomes management work? Health Aff 1994; 13(4):153-162
3. Clardy JA, Booth BM, Smith LG, Nordquist CR, Smith GR: Implementing a statewide outcomes management system for consumers of public mental health services. Psychiatr Serv 1998; 49:191-195
4. Ellwood P: Outcomes management: a technology of patient experience. N Engl J Med 1988; 318:1549-1556
5. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
6. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
7. Arvanitis L, Miller B (Seroquel Trial 13 Study Group): Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233-246
8. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
9. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia): A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809-815
10. Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32:683-697
11. Sernyak MJ, Desai R, Stolar M, Rosenheck R: Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158:931-937
12. Sernyak M, Rosenheck R, Desai R, Stolar M, Ripper G: Impact of clozapine prescription on inpatient resource utilization. J Nerv Ment Dis 2001; 189:766-773
13. Department of Veterans Affairs: Instituting Global Assessment of Functioning (GAF) Scores in Axis V for Mental Health Patients. VHA Directive 97-059. Washington, DC, VA, 1997
14. Moos RH, McCoy L, Moos BS: Global assessment of functioning (GAF) ratings: determinants and roles as predictors of one-year treatment outcomes. J Clin Psychol 2000; 56:449-461
15. Luborsky L: Clinicians' judgments of mental health: a proposed scale. Arch Gen Psychiatry 1962; 7:407-417
16. Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P: Interrater reliability issues in multicenter trials, part 1: theoretical concepts and operational procedures used in Department of Veterans Affairs cooperative study #394. Psychopharmacology Bull 1997; 33:53-57
17. Rey JM, Starling J, Wever C, Dossetor DR, Plapp JM: Inter-rater reliability of global assessment of functioning in a clinical setting. J Child Psychol Psychiatry 1995; 36:787-792
18. Rosenheck R, Stolar M: Access to public mental health services: determinants of population coverage. Med Care 1998; 36:503-512
19. Breier A, Buchanan RW, Irish D, Carpenter W Jr: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44:1145-1149
20. Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J, Henderson W, Charney D: How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999; 25:709-719
21. Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000; 321:1371-1376
22. Sauriol L, Laporta M, Edwardes MD, Deslandes M, Ricard N, Suissa S: Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. Clin Ther 2001; 23:942-956
23. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276